Not Yet RecruitingNot Applicable

Esketamine Combined With PRF of DRG for Postherpetic Neuralgia

China186 participantsStarted 2025-04-01

Plain-language summary

This trial's primary objective is to compare the analgesic efficacy of esketamine in combination with pulsed radiofrequency (PRF) of dorsal root ganglion(DRG) against that of PRF monotherapy in patients with postherpetic neuralgia(PHN).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Ages more than 18 years;
✓. Pain persisting for over three months following the onset of the herpes zoster skin rash;
✓. Lesions located in in the unilateral cervical, thoracic, and lumbosacral segments;
✓. Having an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10= worst possible pain)； Planned to perform CT-guided PRF treatment of the Dorsal root ganglion（DRG）

Exclusion criteria

✕. Obstructive sleep apnoea syndrome;
✕. Those who receive other more invasive treatments, such as radiofrequency thermocoagulation (RFT) of DRG.
✕. A history of systemic immune diseases, organ transplantation, or cancers;
✕. A history of severe cardiopulmonary, hepatic, renal dysfunction or coagulation function disorder;
✕. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;
✕. Comorbid hyperthyroidism or phaeochromocytoma;
✕. Recent history of drug abuse;
✕. Having contraindications to esketamine;

What they're measuring

The primary comparison is the difference between the means of the daily mean pain scores over the first 7 days, measured on an 11-point NRS

Timeframe: 7-day period

Trial details

NCT IDNCT06914193

SponsorBeijing Tiantan Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07-01

Contact for this trial

Fang Luo

+86 13611326978 13611326978@163.com

View on ClinicalTrials.gov More Postherpetic Neuralgia trials